Xu Shu

430 total citations
10 papers, 300 citations indexed

About

Xu Shu is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Statistics and Probability. According to data from OpenAlex, Xu Shu has authored 10 papers receiving a total of 300 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Pulmonary and Respiratory Medicine, 3 papers in Physiology and 3 papers in Statistics and Probability. Recurrent topics in Xu Shu's work include Statistical Methods and Bayesian Inference (3 papers), Respiratory and Cough-Related Research (3 papers) and Statistical Methods and Inference (3 papers). Xu Shu is often cited by papers focused on Statistical Methods and Bayesian Inference (3 papers), Respiratory and Cough-Related Research (3 papers) and Statistical Methods and Inference (3 papers). Xu Shu collaborates with scholars based in United States, Switzerland and South Africa. Xu Shu's co-authors include Douglas E. Schaubel, John C. Magee, Randall S. Sung, Richard N. van Zyl-Smit, Peter D’Andrea, Abhijit Pethe, Pratima Sharma, Kenneth R. Chapman, Huib A.M. Kerstjens and Jorge Máspero and has published in prestigious journals such as Biometrics, Transplantation and The Lancet Respiratory Medicine.

In The Last Decade

Xu Shu

8 papers receiving 300 citations

Peers

Countries citing papers authored by Xu Shu

Since Specialization

Citations

This map shows the geographic impact of Xu Shu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xu Shu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xu Shu more than expected).

Fields of papers citing papers by Xu Shu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xu Shu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xu Shu. The network helps show where Xu Shu may publish in the future.

Co-authorship network of co-authors of Xu Shu

This figure shows the co-authorship network connecting the top 25 collaborators of Xu Shu. A scholar is included among the top collaborators of Xu Shu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xu Shu. Xu Shu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

#	Work	Indexed citations
1	Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial 2022 ·The Lancet Rheumatology ·MeiLan K. Han, Martti Antila, Joachim H. Ficker, И. Г. Гордеев, (unknown), Amparo López‐Bernús, Antoine Roquilly, José Sifuentes‐Osornio, Fehmı Tabak, Ricardo Teijeiro, (unknown), (unknown), Xu Shu, James M. Felser, Barbara Knorr, Weihua Cao, Peter Langmuir, Thomas Lehmann, Michael P. Levine, Sinisa Savic	32
2	One time a day mometasone/indacaterol fixed-dose combination versus two times a day fluticasone/salmeterol in patients with inadequately controlled asthma: pooled analysis from PALLADIUM and IRIDIUM studies 2021 ·BMJ Open Respiratory Research ·Kenneth R. Chapman, Richard N. van Zyl-Smit, Jorge Máspero, Huib A.M. Kerstjens, Yasuhiro Gon, (unknown), (unknown), Abhijit Pethe, Xu Shu, Peter D’Andrea	4
3	Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study 2020 ·The Lancet Respiratory Medicine ·Richard N. van Zyl-Smit, Matthias Krüll, Christian Geßner, Yasuhiro Gon, O. Noga, Alexia Richard, (unknown), Xu Shu, Abhijit Pethe, (unknown), Peter D’Andrea	33
4	Once-daily, single-inhaler mometasone–indacaterol–glycopyrronium versus mometasone–indacaterol or twice-daily fluticasone–salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study 2020 ·The Lancet Respiratory Medicine ·Huib A.M. Kerstjens, Jorge Máspero, Kenneth R. Chapman, Richard N. van Zyl-Smit, (unknown), (unknown), (unknown), Abhijit Pethe, Xu Shu, Peter D’Andrea	102
5	Methods for Contrasting Gap Time Hazard Functions: Application to Repeat Liver Transplantation 2016 ·Statistics in Biosciences ·Xu Shu, Douglas E. Schaubel	0
6	A Reassessment of the Survival Advantage of Simultaneous Kidney-Pancreas Versus Kidney-Alone Transplantation 2015 ·Transplantation ·Randall S. Sung, Min Zhang, Douglas E. Schaubel, Xu Shu, John C. Magee	30
7	Semiparametric Methods to Contrast Gap Time Survival Functions: Application to Repeat Kidney Transplantation 2015 ·Biometrics ·Xu Shu, Douglas E. Schaubel	0
8	Propensity score‐based survival benefit of simultaneous liver‐kidney transplant over liver transplant alone for recipients with pretransplant renal dysfunction 2015 ·Liver Transplantation ·Pratima Sharma, Xu Shu, Douglas E. Schaubel, Randall S. Sung, John C. Magee	59
9	Semiparametric methods for survival analysis of case‐control data subject to dependent censoring 2014 ·Canadian Journal of Statistics ·Douglas E. Schaubel, Hui Zhang, John D. Kalbfleisch, Xu Shu	3
10	Association of Genetic Variation in Pharmacodynamic Factors with Methadone Dose Required for Effective Treatment of Opioid Addiction 2013 ·Pharmacogenomics ·Orna Levran, Einat Peles, Matthew Randesi, Xu Shu, Jürg Ott, Pei‐Hong Shen, Miriam Adelson, Mary Jeanne Kreek	37

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact